Home Compare DXCM vs NBIX
Stock Comparison · Comparison

DexCom vs Neurocrine Biosciences: Which Stock Looks Stronger in 2026?

DexCom leads structurally, with profitability as the clearest single gap between the two profiles. Neurocrine Biosciences still has the edge on stability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Profitability still does most of the heavy lifting in this comparison. The overall score gap is 13 points in favour of DexCom, Inc..

Trajectory Similarity
0.67
Moderately similar
Peer-set rank: #12
within DexCom, Inc.'s functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

Most of the shared profile comes through capital structure and revenue stability.

Similarity drivers
capital structurerevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
DXCM
DexCom, Inc.
69
Peer-Score
Signal qualityHigh
vs
NBIX
Neurocrine Biosciences, Inc.
56
Peer-Score
Signal qualityMedium

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: DXCM vs NBIX Profitability 97 32 Stability 14 47 Valuation 69 63 Growth 83 88 DXCM NBIX
Gap Ranking
#1 Profitability +65
#2 Stability +33
#3 Valuation +6
#4 Growth +5
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for DXCM and NBIX Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer DXCMNBIX Relative valuation Structural strength

Neither company combines the stronger profile with the cheaper valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
On profitability, DexCom, Inc. ranks near the top of the group; Neurocrine Biosciences, Inc. sits in the weaker half.
Stability
Neurocrine Biosciences, Inc. sits higher in the group on stability, adding to the overall structural advantage.
Profitability — Dominant Gap
DXCM
97
NBIX
32
Gap+65in favour of DXCM

Capital efficiency adds support, with a 20.5-point ROIC advantage.

What keeps the gap from being one-sided

Stability still leans toward Neurocrine Biosciences, Inc., so the lead is real without reading as one-way.

What this means for the comparison

The profitability edge is decisive, even though current pricing and stability still lean somewhat toward Neurocrine Biosciences, Inc..

Explore full peer positioning in AssetNext

Break down the DXCM vs NBIX comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how DXCM and NBIX each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.